1. Prevalence of amyloid PET positivity in dementia syndromes: a meta-analysis
- Author
-
Susan M. Landau, William E. Klunk, Philipp T. Meyer, Alberto Lleó, Adam S. Fleisher, Andrew B. Newberg, John R. Hodges, Karine Madsen, Mark A. Mintun, Bruce L. Miller, Sander C.J. Verfaillie, Timo Grimmer, Juha O. Rinne, Bart N.M. van Berckel, Pascual Sánchez-Juan, Catherine M. Roe, Howard J. Rosen, Ann D. Cohen, Cristian E. Leyton, Norman Koglin, Agneta Nordberg, Willemijn J. Jansen, Stefan Förster, Sang W. Seo, Koen Van Laere, Frederik Barkhof, Rafael Blesa, Juan Fortea, Adriaan A. Lammertsma, David A. Wolk, Gaël Chételat, Sabine Hellwig, Vincent Camus, Kristian Steen Frederiksen, Rik Ossenkoppele, Sofie Adriaanse, David J. Brooks, Gil D. Rabinovici, Wiesje M. van der Flier, William J. Jagust, Vincent Mok, Osama Sabri, Rik Vandenberghe, Dirk L. Knol, Marissa D. Zwan, Philip Scheltens, Marie Sarazin, Christopher C. Rowe, Duk L. Na, Henryk Barthel, Karen M. Rodrigue, José M. Carril, Dong Y. Lee, Pieter Jelle Visser, Alexander Drzezga, Victor L. Villemagne, Neurology, Radiology and nuclear medicine, Epidemiology and Data Science, NCA - neurodegeneration, Universidad de Cantabria, Promovendi MHN, Psychiatrie & Neuropsychologie, RS: MHeNs - R1 - Cognitive Neuropsychiatry and Clinical Neuroscience, and Neuroscience Campus Amsterdam - Neurodegeneration
- Subjects
Adult ,Apolipoprotein E ,Male ,medicine.medical_specialty ,Pathology ,Genotype ,Amyloid ,Apolipoprotein E4 ,ta3112 ,Article ,Risk Factors ,Internal medicine ,mental disorders ,Prevalence ,medicine ,Dementia ,Humans ,Cognitive Dysfunction ,Vascular dementia ,Aged ,Aged, 80 and over ,Amyloid beta-Peptides ,business.industry ,Age Factors ,Brain ,General Medicine ,Middle Aged ,medicine.disease ,ta3124 ,Positron-Emission Tomography ,Meta-analysis ,Female ,Differential diagnosis ,Alzheimer's disease ,business ,Frontotemporal dementia - Abstract
IMPORTANCE: Amyloid-β positron emission tomography (PET) imaging allows in vivo detection of fibrillar plaques, a core neuropathological feature of Alzheimer disease (AD). Its diagnostic utility is still unclear because amyloid plaques also occur in patients with non-AD dementia. OBJECTIVE: To use individual participant data meta-analysis to estimate the prevalence of amyloid positivity on PET in a wide variety of dementia syndromes. DATA SOURCES: The MEDLINE and Web of Science databases were searched from January 2004 to April 2015 for amyloid PET studies. STUDY SELECTION: Case reports and studies on neurological or psychiatric diseases other than dementia were excluded. Corresponding authors of eligible cohorts were invited to provide individual participant data. DATA EXTRACTION AND SYNTHESIS: Data were provided for 1359 participants with clinically diagnosed AD and 538 participants with non-AD dementia. The reference groups were 1849 healthy control participants (based on amyloid PET) and an independent sample of 1369 AD participants (based on autopsy). MAIN OUTCOMES AND MEASURES: Estimated prevalence of positive amyloid PET scans according to diagnosis, age, and apolipoprotein E (APOE) ε4 status, using the generalized estimating equations method. RESULTS: The likelihood of amyloid positivity was associated with age and APOE ε4 status. In AD dementia, the prevalence of amyloid positivity decreased from age 50 to 90 years in APOE ε4 noncarriers (86% [95% CI, 73%-94%] at 50 years to 68% [95% CI, 57%-77%] at 90 years; n = 377) and to a lesser degree in APOE ε4 carriers (97% [95% CI, 92%-99%] at 50 years to 90% [95% CI, 83%-94%] at 90 years; n = 593; P
- Published
- 2015
- Full Text
- View/download PDF